Yao, Jingwen
Wang, Chencai
Raymond, Catalina
Bergstrom, Blake
Chen, Xing
Das, Kaveri
Dinh, Huy
Kim, Zoe S.
Le, Angela N.
Lim, Matthew W. J.
Pham, Jane A. N.
Prusan, Joseph D.
Rao, Sriram S.
Nathanson, David A.
Ellingson, Benjamin M. http://orcid.org/0000-0002-2764-6640
Funding for this research was provided by:
American Cancer Society (RSG-15-003-01-CCE)
National Cancer Institute (1P50CA211015-01A1, 1R21CA223757-01)
Article History
Received: 24 August 2020
Revised: 13 November 2020
Accepted: 9 December 2020
First Online: 23 January 2021
Compliance with ethical standards
:
: Author B.M.E. is a paid consultant at companies Medicenna, MedQIA, Neosoma, Agios Pharmaceuticals, Siemens, Imaging Endpoints, Kazia/Novogen, and NW Biopharmaceuticals. He is a consultant at companies Oncoceutics, BeiGene, BBI, Tocagen, and non-profit organizations Global Coalition for Adaptive Research (GCAR) and NIH/NCI Cancer Imaging Steering Committee. Author B.M.E. also receives research grant from companies Siemens, Janssen Pharmaceuticals, VBL, and non-profit organizations National Brain Tumor Society and ACS. Author D.A.N. is a co-founder and consultant at company Katmai Pharmaceuticals and a co-founder of company Trethera Corporation. He is also a shareholder in Sofie Biosciences. Authors J.Y., C.R.G., X.C., A.N.L., H.D., C.W., K.D., M.W.J.L, B.B., Z.S.K., J.A.N.P., J.D.P., S.S.R. has no conflict of interest to disclose.
: This article does not contain any studies with human participants or animals performed by any of the authors.